Characterizing Eckol as a Therapeutic Aid: A Systematic Review

Manandhar, Bandana; Paudel, Pradeep; Seong, Su Hui; Jung, Hyun Ah; Choi, Jae Sue

Similarly, the Ecklonia stolonifera-derived EtOAc fraction exhibited inhibitory effects against advanced glycation end-products (AGEs) formation and rat lens aldose reductase (RLAR) and yielded phloroglucinol, dioxinodehydroeckol, eckol, phlorofucofuroeckol-A, dieckol, triphlorethol-B, 2-phloroeckol, and 7-phloroeckol [46] . The E. stolonifera-derived phlorotannins exhibited RLAR inhibitory activity, with eckol showing an IC 50 of 54.68 µM, although most of the isolated phlorotannins showed no activity in the AGEs inhibition assay. These results were in contrast to another study [89] in which the inhibitory effect of the isolated compounds on glycation, was 96.2% for eckol, 86.7% for dieckol, and 76.0% for aminoguanidine at 1 mM. According to Jung et al. [46] , the reasons for the discrepant results could include differences in the glycation conditions and glycation steps and the detectors used in the fluorescence, ELISA, and Western blot analyses. The α-amylase inhibition of the compounds was also checked where the percent inhibitions were found to be 87.5% for eckol at 1 mM. So, according to the results, eckol could be a promising treatment agent for diabetic complications and may possess significant inhibitory effects against AGEs, RLAR, and α-amylase [89] .